



an Open Access Journal by MDPI

## Antibiotics Treatment Optimization in Vulnerable Populations

Guest Editors:

### Dr. Romain Guilhaumou

1. Service de Pharmacologie clinique et Pharmacovigilance, Hôpital de la Timone, Marseille, France 2. Aix Marseille Université, Institut de Neurosciences des Systèmes, Inserm UMR 1106, Marseille, France

### Dr. Amélie Marsot

1. Laboratoire de Suivi Thérapeutique Pharmacologique et Pharmacocinétique, Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada 2. Centre de recherche, CHU Sainte-Justine, Montréal, QC, Canada

Deadline for manuscript submissions:

**closed (31 May 2023)**

### Message from the Guest Editors

Pharmacokinetic/pharmacodynamic studies allow new recommendations to be developed based on a patient's characteristics as well as clinical context and to move away from the 'one dose fits all' approach that seems to be more and more obsolete since the beginning of personalized medicine. In this Special Issue we aim to highlight new data that support new recommendations for antibiotic use to optimize care by ensuring that 'the right treatments are given to the right patient at the right dose and at the right time'.

### Keywords

- antibiotics
- pharmacokinetics
- pharmacodynamics
- dose optimization
- vulnerable populations
- personalised dosing



[mdpi.com/si/112177](https://mdpi.com/si/112177)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi